Immix Biopharma (IMMX) to Release Quarterly Earnings on Monday

Immix Biopharma (NASDAQ:IMMX) will likely be releasing its Q4 2025 results before the market opens on Monday, March 23rd. Analysts expect Immix Biopharma to post earnings of ($0.16) per share for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

Immix Biopharma Price Performance

Shares of NASDAQ:IMMX opened at $9.11 on Friday. The business has a 50-day moving average of $7.37 and a two-hundred day moving average of $5.02. The firm has a market capitalization of $482.47 million, a PE ratio of -11.83 and a beta of 0.25. Immix Biopharma has a 12 month low of $1.34 and a 12 month high of $11.61.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IMMX. Mizuho initiated coverage on shares of Immix Biopharma in a research report on Monday, February 9th. They set an “outperform” rating and a $14.00 target price for the company. Wall Street Zen cut shares of Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Immix Biopharma in a research report on Thursday, January 22nd. Finally, Citizens Jmp assumed coverage on shares of Immix Biopharma in a research note on Monday, March 9th. They issued an “outperform” rating and a $23.00 target price on the stock. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Institutional Trading of Immix Biopharma

Hedge funds have recently made changes to their positions in the company. Janus Henderson Group PLC acquired a new stake in shares of Immix Biopharma in the 4th quarter valued at about $20,471,000. Marshall Wace LLP grew its stake in Immix Biopharma by 3,495.4% in the fourth quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock worth $10,349,000 after purchasing an additional 1,923,708 shares in the last quarter. Millennium Management LLC bought a new stake in Immix Biopharma in the fourth quarter valued at about $8,681,000. Adage Capital Partners GP L.L.C. acquired a new stake in Immix Biopharma during the fourth quarter valued at approximately $7,845,000. Finally, Bleichroeder LP lifted its holdings in Immix Biopharma by 17.6% during the 4th quarter. Bleichroeder LP now owns 1,000,000 shares of the company’s stock worth $5,230,000 after buying an additional 150,000 shares during the last quarter. Hedge funds and other institutional investors own 11.26% of the company’s stock.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.